SOBI 003

Drug Profile

SOBI 003

Alternative Names: Modified recombinant human sulphamidase; Recombinant-sulfamidase-Swedish-Orphan-Biovitrum; SOBI-003

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Swedish Orphan Biovitrum
  • Class Hydrolases
  • Mechanism of Action Hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis III

Most Recent Events

  • 19 Jun 2018 Phase-I/II clinical trials in Mucopolysaccharidosis III (In infants, In children) in USA (IV) (NCT03423186)
  • 23 Jan 2018 Preclinical trials in Mucopolysaccharidosis III in USA (Parenteral)
  • 23 Jan 2018 Enzyme replacement therapies - Swedish Orphan Biovitrum receives Fast Track designation for Mucopolysaccharidosis III [Parenteral] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top